...
机译:细胞角蛋白5/6,雄激素受体和p53的免疫组织化学共表达状态是三阴性乳腺癌辅助化疗的预后因素
Department of Breast Surgery, Nihon University School of Medicine, Tokyo, Japan;
Department of Pathology, Nihon University School of Medicine, 30-1 Ohyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan;
Department of Pathology, Nihon University School of Medicine, 30-1 Ohyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan;
Department of Pathology, Nihon University School of Medicine, 30-1 Ohyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan;
Department of Breast Surgery, Nihon University School of Medicine, Tokyo, Japan;
Department of Breast Surgery, Nihon University School of Medicine, Tokyo, Japan;
Department of Breast Surgery, Nihon University School of Medicine, Tokyo, Japan;
Department of Pathology, Nihon University School of Medicine, 30-1 Ohyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan;
Adjuvant chemotherapy; AR; CK5/6; p53; Prognosis; TNBC;
机译:免疫组化检测p53在辅助化疗治疗的三阴性乳腺癌中的预后价值
机译:雄激素受体和组织蛋白酶D共表达在非转移性三重阴性乳腺癌中的预后价值及与其他生物标志物的相关性
机译:p53状态可确定对辅助化疗无反应的三阴性乳腺癌患者
机译:雌激素受体阳性乳腺癌:传统预测,分子病理:新的乳腺癌分类和21世纪个性化预测和预测测定
机译:一个 TGFβ- 雄激素受体信号 轴 影响 抗失巢凋亡 在 三阴性乳腺癌
机译:雄激素受体和FOXA1共表达在非转移性三阴性乳腺癌中的预后价值及其与其他生物标志物的相关性
机译:>由Bcl-2,p53和肿瘤浸润淋巴细胞代表的生物分子因子预测辅助蒽环素化疗的响应,患者早期三阴性乳腺癌患者 p>